Condition: Coronary Heart Disease (CHD) · Diabetes (DM) · Sponsor: Shanghai Zhongshan Hospital
To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.
This description comes directly from the study's public registry record.
Chenguang Li, Doctor · 13816767665 · li.chenguang@zs-hospital.sh.cn
Rende Xu, Doctor · 86-15800624206 · xu.rende@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649305